Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
If you have the potential to become pregnant, discuss your birth control plans with your clinician before starting treatment
Sustainable Weight Loss: The treatment supports gradual, consistent fat loss over time rather than rapid, temporary changes
Tirzepatide (Mounjaro, Zepbound) is technically a dual GIP/GLP-1 receptor agonist, hitting two incretin receptors instead of one, which explains its superior weight loss outcomes in clinical trials
A recent meta-analysis of randomized controlled trials (RCTs), including AMPLITUDE-O, examining six GLP-1 receptor agonists (lixisenatide, liraglutide, subcutaneous semaglutide, exenatide, dulaglutide, and efpeglenatide) reported a 21% reduction in a composite kidney outcome (macroalbuminuria, doubling of serum creatinine or 40% eGFR decline, RRT, or death from kidney disease), corresponding to a number needed to treat of 47 [73]
